Compare AIV & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIV | VTYX |
|---|---|---|
| Founded | 1975 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 990.9M |
| IPO Year | 1994 | 2021 |
| Metric | AIV | VTYX |
|---|---|---|
| Price | $5.91 | $14.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 1 | 7 |
| Target Price | $10.00 | ★ $13.50 |
| AVG Volume (30 Days) | 1.9M | ★ 5.9M |
| Earning Date | 02-23-2026 | 02-26-2026 |
| Dividend Yield | ★ 37.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.72 | N/A |
| Revenue | ★ $210,889,000.00 | N/A |
| Revenue This Year | $6.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.78 | ★ N/A |
| Revenue Growth | ★ 39.67 | N/A |
| 52 Week Low | $5.24 | $0.78 |
| 52 Week High | $9.29 | $25.00 |
| Indicator | AIV | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 52.74 | 76.51 |
| Support Level | $5.86 | $7.08 |
| Resistance Level | $5.96 | $13.90 |
| Average True Range (ATR) | 0.07 | 0.32 |
| MACD | -0.01 | 0.12 |
| Stochastic Oscillator | 53.33 | 84.02 |
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.